Selective permeability of mucus barriers

Witten, 2017, The particle in the spider's web: transport through biological hydrogels, Nanoscale, 9, 8080, 10.1039/C6NR09736G Wu, 2017, Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties, Adv Drug Deliv Rev Araújo, 2017, Chemical modification of drug molecules as strategy to reduce interactions with mucus, Adv Drug Deliv Rev Murgia, 2017, The role of mucus on drug transport and its potential to affect therapeutic outcomes, Adv Drug Deliv Rev Huckaby, 2017, PEGylation for enhancing nanoparticle diffusion in mucus, Adv Drug Deliv Rev Leal, 2017, Physicochemical properties of mucus and their impact on transmucosal drug delivery, Int J Pharm, 532, 555, 10.1016/j.ijpharm.2017.09.018 Mastorakos, 2015, Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy, Proc Natl Acad Sci U S A, 112, 8720, 10.1073/pnas.1502281112 Johansson, 2014, Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis, Gut, 63, 281, 10.1136/gutjnl-2012-303207 Curlin, 2013, Cervical mucus: from biochemical structure to clinical implications, Front Biosci Sch Ed, 5, 507, 10.2741/S386 Bansil, 2006, Mucin structure, aggregation, physiological functions and biomedical applications, Curr Opin Colloid Interface Sci, 11, 164, 10.1016/j.cocis.2005.11.001 Wagner, 2017, A rheological study of the association and dynamics of MUC5AC gels, Biomacromolecules, 18, 3654, 10.1021/acs.biomac.7b00809 Lieleg, 2011, Biological hydrogels as selective diffusion barriers, Trends Cell Biol, 21, 543, 10.1016/j.tcb.2011.06.002 Suk, 2011, Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine, Nanomedicine, 6, 365, 10.2217/nnm.10.123 Menzel, 2017, Enzyme decorated drug carriers: targeted swords to cleave and overcome the mucus barrier, Adv Drug Deliv Rev Efiana, 2018, Mucus permeating self-emulsifying drug delivery systems (SEDDS): about the impact of mucolytic enzymes, Colloids Surf B Biointerfaces, 161, 228, 10.1016/j.colsurfb.2017.10.032 Leichner, 2017, Development and in vitro characterization of a papain loaded mucolytic self-emulsifying drug delivery system (SEDDS), Int J Pharm, 530, 346, 10.1016/j.ijpharm.2017.08.059 Mahmood, 2017, Protease-functionalized mucus penetrating microparticles: in-vivo evidence for their potential, Int J Pharm, 10.1016/j.ijpharm.2017.08.114 Grodzinsky, 2011 Radicioni, 2016, The innate immune properties of airway mucosal surfaces are regulated by dynamic interactions between mucins and interacting proteins: the mucin interactome, Mucosal Immunol, 9, 1442, 10.1038/mi.2016.27 Larhed, 1998, The influence of intestinal mucus components on the diffusion of drugs, Pharm Res, 15, 66, 10.1023/A:1011948703571 Wang, 2016, Diffusion of immunoglobulin G in shed vaginal epithelial cells and in cell-free regions of human cervicovaginal mucus, PLOS ONE, 11, e0158338, 10.1371/journal.pone.0158338 Khanvilkar, 2001, Drug transfer through mucus, Adv Drug Deliv Rev, 48, 173, 10.1016/S0169-409X(01)00115-6 Xu, 2015, Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo, ACS Nano, 9, 9217, 10.1021/acsnano.5b03876 Cone, 2009, Barrier properties of mucus, Adv Drug Deliv Rev, 61, 75, 10.1016/j.addr.2008.09.008 Huang, 2015, Mucin binding reduces colistin antimicrobial activity, Antimicrob Agents Chemother, 59, 5925, 10.1128/AAC.00808-15 Schuster, 2014, Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors, Mol Ther, 22, 1484, 10.1038/mt.2014.89 Li, 2013, Spatial configuration and composition of charge modulates transport into a mucin hydrogel barrier, Biophys J, 105, 1357, 10.1016/j.bpj.2013.07.050 Chen, 2009, Ultra-low fouling peptide surfaces derived from natural amino acids, Biomaterials, 30, 5892, 10.1016/j.biomaterials.2009.07.001 Datta-Mannan, 2015, Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics, mAbs, 7, 483, 10.1080/19420862.2015.1016696 Lowe, 2015, Antibiofouling polymer interfaces: poly(ethylene glycol) and other promising candidates, Polym Chem, 6, 198, 10.1039/C4PY01356E Gargano, 2014, Mucin-based stationary phases as tool for the characterization of drug–mucus interaction, J Chromatogr A, 1351, 70, 10.1016/j.chroma.2014.05.031 Jachak, 2012, Transport of metal oxide nanoparticles and single-walled carbon nanotubes in human mucus, Nanotoxicology, 6, 614, 10.3109/17435390.2011.598244 Netsomboon, 2016, Mucoadhesive vs. mucopenetrating particulate drug delivery, Eur J Pharm Biopharm, 98, 76, 10.1016/j.ejpb.2015.11.003 Emanuele, 2001, A survey of structure–property relationships of surfaces that resist the adsorption of protein, Langmuir ACS J Surf Colloids, 17, 5605, 10.1021/la010384m Lock, 2017, Mucus models to evaluate the diffusion of drugs and particles, Adv Drug Deliv Rev Du, 2015, Improved biofilm antimicrobial activity of polyethylene glycol conjugated tobramycin compared to tobramycin in Pseudomonas aeruginosa biofilms, Mol Pharm, 12, 1544, 10.1021/mp500846u Bahamondez-Canas, 2018, PEGylation of tobramycin improves mucus penetration and antimicrobial activity against Pseudomonas aeruginosa biofilms in vitro, Mol Pharm, 10.1021/acs.molpharmaceut.8b00011 Scanlon, 2010, Enhanced antimicrobial activity of engineered human lysozyme, ACS Chem Biol, 5, 809, 10.1021/cb1001119 Gill, 2011, Crystal structure of a charge engineered human lysozyme having enhanced bactericidal activity, PLoS ONE, 6, e16788, 10.1371/journal.pone.0016788 Teneback, 2013, Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection, Antimicrob Agents Chemother, 57, 5559, 10.1128/AAC.00500-13 Griswold, 2014, Bioengineered lysozyme in combination therapies for Pseudomonas aeruginosa lung infections, Bioengineered, 5, 143, 10.4161/bioe.28335 Schneider, 2017, Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation, Sci Adv, 3, e1601556, 10.1126/sciadv.1601556 Maisel, 2015, Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse, J Controlled Release, 197, 48, 10.1016/j.jconrel.2014.10.026 Ensign, 2012, Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus, Sci Transl Med, 4, 10.1126/scitranslmed.3003453 Schopf, 2014, Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation, Ophthalmol Ther, 3, 63, 10.1007/s40123-014-0021-z Suk, 2016, PEGylation as a strategy for improving nanoparticle-based drug and gene delivery, Adv Drug Deliv Rev, 99, 28, 10.1016/j.addr.2015.09.012 Huckaby, 2017, PEGylation for enhancing nanoparticle diffusion in mucus, Adv Drug Deliv Rev Yang, 2014, Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth, Adv Healthc Mater, 3, 1044, 10.1002/adhm.201300519 Shan, 2016, Enhanced oral delivery of protein drugs using zwitterion-functionalized nanoparticles to overcome both the diffusion and absorption barriers, ACS Appl Mater Interfaces, 8, 25444, 10.1021/acsami.6b08183 Abdulkarim, 2015, Nanoparticle diffusion within intestinal mucus: three-dimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, pegylated and viral particles, Eur J Pharm Biopharm, 97, 230, 10.1016/j.ejpb.2015.01.023 Zhang, 2018, Design and intestinal mucus penetration mechanism of core–shell nanocomplex, J Controlled Release, 272, 29, 10.1016/j.jconrel.2017.12.034 Pereira de Sousa, 2016, Insulin loaded mucus permeating nanoparticles: addressing the surface characteristics as feature to improve mucus permeation, Int J Pharm, 500, 236, 10.1016/j.ijpharm.2016.01.022 Khutoryanskiy, 2017, Beyond PEGylation: alternative surface-modification of nanoparticles with mucus-inert biomaterials, Adv Drug Deliv Rev Mansfield, 2016, Side chain variations radically alter the diffusion of poly(2-alkyl-2-oxazoline) functionalised nanoparticles through a mucosal barrier, Biomater Sci, 4, 1318, 10.1039/C6BM00375C Popov, 2016, Mucus-penetrating nanoparticles made with “mucoadhesive” poly(vinyl alcohol), Nanomedicine, 12, 1863, 10.1016/j.nano.2016.04.006 Liu, 2016, Efficient mucus permeation and tight junction opening by dissociable “mucus-inert” agent coated trimethyl chitosan nanoparticles for oral insulin delivery, J Controlled Release, 222, 67, 10.1016/j.jconrel.2015.12.008 Cui, 2017, A strategy for developing effective orally-delivered nanoparticles through modulation of the surface “hydrophilicity/hydrophobicity balance.”, J Mater Chem B, 5, 1302, 10.1039/C6TB02475K Zhu, 2016, Sub-50nm nanoparticles with biomimetic surfaces to sequentially overcome the mucosal diffusion barrier and the epithelial absorption barrier, Adv Funct Mater, 26, 2728, 10.1002/adfm.201505000 Wu, 2017, Lipid nanovehicles with adjustable surface properties for overcoming multiple barriers simultaneously in oral administration, Int J Pharm, 520, 216, 10.1016/j.ijpharm.2017.02.015 Bonengel, 2015, Polyethylene imine-6-phosphogluconic acid nanoparticles—a novel zeta potential changing system, Int J Pharm, 483, 19, 10.1016/j.ijpharm.2015.01.041 Suchaoin, 2016, Development and in vitro evaluation of zeta potential changing self-emulsifying drug delivery systems for enhanced mucus permeation, Int J Pharm, 510, 255, 10.1016/j.ijpharm.2016.06.045 Griesser, 2017, Zeta potential changing self-emulsifying drug delivery systems containing phosphorylated polysaccharides, Eur J Pharm Biopharm, 119, 264, 10.1016/j.ejpb.2017.06.025 Shao, 2015, Molecular understanding and design of zwitterionic materials, Adv Mater, 27, 15, 10.1002/adma.201404059 Henry, 2016, Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus, Acta Biomater, 43, 61, 10.1016/j.actbio.2016.07.019 Wang, 2014, IgG in cervicovaginal mucus traps HSV and prevents vaginal Herpes infections, Mucosal Immunol, 7, 1036, 10.1038/mi.2013.120 Wang, 2016, Influenza-binding antibodies immobilise influenza viruses in fresh human airway mucus, Eur Respir J Chen, 2014, Transient antibody–mucin interactions produce a dynamic molecular shield against viral invasion, Biophys J, 106, 2028, 10.1016/j.bpj.2014.02.038 Smith-Dupont, 2017, Probing the potential of mucus permeability to signify preterm birth risk, Sci Rep, 7, 10302, 10.1038/s41598-017-08057-z Linden, 2008, Mucins in the mucosal barrier to infection, Mucosal Immunol, 1, 183, 10.1038/mi.2008.5 Fahy, 2010, Airway mucus function and dysfunction, N Engl J Med, 363, 2233, 10.1056/NEJMra0910061 Kesimer, 2017, Airway mucin concentration as a marker of chronic bronchitis, N Engl J Med, 377, 911, 10.1056/NEJMoa1701632 Matsui, 2006, A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms, Proc Natl Acad Sci U S A, 103, 18131, 10.1073/pnas.0606428103 Button, 2016, Mucus hyperconcentration as a unifying aspect of the chronic bronchitic phenotype, Ann Am Thorac Soc, 13, S156 Yuan, 2015, Oxidation increases mucin polymer cross-links to stiffen airway mucus gels, Sci Transl Med, 7, 276ra27, 10.1126/scitranslmed.3010525 Chen, 2010, A new role for bicarbonate in mucus formation, Am J Physiol Lung Cell Mol Physiol, 299, L542, 10.1152/ajplung.00180.2010 Bergstrom, 2016, Defective intestinal mucin-type O-glycosylation causes spontaneous colitis-associated cancer in mice, Gastroenterology, 151, 10.1053/j.gastro.2016.03.039 Lidell, 2006, Entamoeba histolytica cysteine proteases cleave the MUC2 mucin in its C-terminal domain and dissolve the protective colonic mucus gel, Proc Natl Acad Sci U S A, 103, 9298, 10.1073/pnas.0600623103 Nunn, 2015, Enhanced trapping of HIV-1 by human cervicovaginal mucus is associated with Lactobacillus crispatus-dominant microbiota, mBio, 6, e01084, 10.1128/mBio.01084-15 Jakobsson, 2015, The composition of the gut microbiota shapes the colon mucus barrier, EMBO Rep, 16, 164, 10.15252/embr.201439263 Gustafsson, 2012, Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype, J Exp Med, 209, 1263, 10.1084/jem.20120562 Lira-Junior, 2016, Periodontal and inflammatory bowel diseases: is there evidence of complex pathogenic interactions?, World J Gastroenterol, 22, 7963, 10.3748/wjg.v22.i35.7963 Frenkel, 2015, Salivary mucins in host defense and disease prevention, J Oral Microbiol, 7, 29759, 10.3402/jom.v7.29759 Brito, 2008, Prevalence of periodontitis and DMFT index in patients with Crohn's disease and ulcerative colitis, J Clin Periodontol, 35, 555, 10.1111/j.1600-051X.2008.01231.x Nordgård, 2018, Co association of mucus modulating agents and nanoparticles for mucosal drug delivery, Adv Drug Deliv Rev, 10.1016/j.addr.2018.01.001 Raynal, 2003, Calcium-dependent protein interactions in MUC5B provide reversible cross-links in salivary mucus, J Biol Chem, 278, 28703, 10.1074/jbc.M304632200 Nordgård, 2014, Alterations in mucus barrier function and matrix structure induced by guluronate oligomers, Biomacromolecules, 15, 2294, 10.1021/bm500464b Ermund, 2015, Hypertonic saline releases the attached small intestinal cystic fibrosis mucus, Clin Exp Pharmacol Physiol, 42, 69, 10.1111/1440-1681.12322